In the pharmaceutical, biotech, and life sciences industries, the terms validation and commissioning are frequently — and mistakenly — used interchangeably.
The CDMO is expanding manufacturing sites in Lexington, Kentucky, and Riverview, Michigan, which are essential to its integrated antibody-drug conjugate offering.
The 25,000-square-meter site at Tuas Biomedical Park is slated to start operations by the end of 2025 and GMP manufacturing in early 2026, according to the company.
